Renalytix (LON:RENX) Trading 4.8% Higher – What’s Next?

Renalytix Plc (LON:RENX)’s stock price was up 4.8% during mid-day trading on Wednesday . The stock traded as high as GBX 11 ($0.14) and last traded at GBX 11 ($0.14). Approximately 240,993 shares traded hands during trading, a decline of 44% from the average daily volume of 432,985 shares. The stock had previously closed at GBX 10.50 ($0.13).

Renalytix Stock Performance

The company has a market cap of £18.25 million, a PE ratio of -45.83 and a beta of 2.10. The company has a 50-day moving average of GBX 8.45 and a 200-day moving average of GBX 10.57. The company has a quick ratio of 2.42, a current ratio of 0.53 and a debt-to-equity ratio of 173.95.

Insider Transactions at Renalytix

In other Renalytix news, insider James Renwick McCullough bought 25,000 shares of the firm’s stock in a transaction dated Tuesday, December 10th. The stock was purchased at an average cost of GBX 9 ($0.11) per share, with a total value of £2,250 ($2,815.32). Also, insider Christopher H. B. Mills sold 83,696 shares of the business’s stock in a transaction dated Monday, October 7th. The stock was sold at an average price of GBX 8 ($0.10), for a total transaction of £6,695.68 ($8,377.98). Company insiders own 35.74% of the company’s stock.

About Renalytix

Renalytix (LSE: RENX) (NASDAQ: RNLX) is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. The Company’s lead product is KidneyIntelX, which has been granted Breakthrough Designation by the U.S.